AI assistant
SCI — Interim / Quarterly Report 2012
Jan 23, 2013
52383_rns_2013-01-23_46bbe4f0-c28c-4812-a493-f8c076d78269.pdf
Interim / Quarterly Report
Open in viewerOpens in your device viewer
SCIPHARMTECH, ING.
簡報
ISO 14001 ISO 9001 BUREAU VERITAS BUREAU VERITAS Certification Certification
procedure ThainForm ForwardScon
If HescoryList.Count > 0 them Foregricket inn, Inchind to Michael
An Indian Medicine Enabled is False.
CODE BOUL CORE THE ATTENDANCE WILL FOR coast plasp: Dispatch; var ULL Reading at Gleversence-war
GestoryTodes ++ U) JALES HIFTOIVILLE COUNTY BAY ListoryList Delwie (History) Riccompladas in Riccorplice.Add
n, Micheylodes is Besinder.
Af Giovernale Com
UpilateCusto Im Zaluki Mei-Tudek in 1102. KE TILLISTER R. P.L. ED UE j. items, framers (0, US)
olas:
beals
$endf$
CANDIDATE ITODOLIWAY


員工數Employee:180 設立日期:中華民國七十六年九月十八日 Date of establishment: Sep. 18, 1987 資本額Capital:新台幣493佰萬元(NTD 493mn) 營業項目Business: 原料藥API(40.22%) 中間體Intermediate(48.64%) 特用化學品 Custom-made chemicals(11.14%)
公司概況 Outline
| Y2012 | Y2011 | |
|---|---|---|
| 歐洲Europe | 41.74% | 31.17% |
| 美洲America | 22.11% | 23.97% |
| 亞洲Asia | 18.15% | 22.32% |
| 國內Taiwan | 18.00% | 22.54% |
| 合 計Total |
100.00% | 100.00% |


Unit: K NTD
| 第一季 Q1 | 第二季Q 2 |
第三季Q 3 |
第四季Q 4 |
||||
|---|---|---|---|---|---|---|---|
| 營收Sales | 358,346 | 281,663 | 313,216 | 309,347 | |||
| 營業成本COGS | 244,460 | 204,843 | 215,912 | 199,469 | |||
| 毛利Gross Profit | 113,886 | 76,820 | 97,304 | 109,878 | |||
| 毛利率 GP Ratio | 31.8% | 27.3% | 31.1% | 35.5% | |||
| 營業費用Operating Expenses | (39,049) | (34,291) | (32,914) | (35,926) | |||
| 營業利益Operating Income | 74,837 | 42,529 | 64,390 | 73,952 | |||
| 營業外損益Non-Operating In/Ex | (7,124) | 818 | (3,891) | (7,513) | |||
| 稅前淨利 Net Profit before Tax | 67,713 | 43,347 | 60,499 | 66,439 | |||
| 所得稅Income Tax | (10,844) | (8,299) | (13,658) | ||||
| 稅後淨利Net Profit after Tax | 56,869 | 35,048 | 46,841 |
產品組合-Products
| Y2010 | $\frac{0}{0}$ |
|---|---|
| V.A. | 20.63% |
| PGA | 18.78% |
| Di-VaNa | 15.96% |
| PPON | $12.42\%$ |
| M85 | 4.92% |
| Pent-2 | $3.77\%$ |
| M74 | 2.42% |
| DEK | 2.12% |
| M 115 | $2.04\%$ |
| Biso-FA | 2.03% |
| Total | 85.09% |
| Y2010 | % | Y2011 | % | Y2012 | % |
|---|---|---|---|---|---|
| V.A. | 20.63% | Di-VaNa | 24.51% | V.A. | 18.66% |
| PGA | 18.78% | PGA | 17.65% | PGA | 16.61% |
| Di-VaNa | 15.96% | V.A. | 13.76% | Di-VaNa | 15.97% |
| PPON | 12.42% | PPON | 10.70% | PPON | 7.88% |
| M85 | 4.92% | M85 | 5.25% | Pent-2 | 4.78% |
| Pent-2 | 3.77% | Pent-2 | 3.73% | 5-HMT | 4.33% |
| M74 | 2.42% | DBS | 3.08% | M85 | 3.89% |
| DEK | 2.12% | M115 | 2.55% | DBS | 2.73% |
| M115 | 2.04% | M74 | 2.31% | M115 | 2.59% |
| Biso-FA | 2.03% | NBE | 1.87% | M74 | 2.18% |
| Total | 85.09% | Total | 85.40% | Total | 79.62% |
| Y2012 | $\frac{0}{0}$ |
|---|---|
| VA. | 18.66% |
| PGA | 16.61% |
| Di-VaNa | 15.97% |
| PPON | 7.88% |
| Pent-2 | 4.78% |
| 5-HMT | 4.33% |
| M85 | 3.89% |
| DBS | 2.73% |
| M115 | 2.59% |
| M74 | 2.18% |
| Total | 79.62% |

V DEDPM.
SCI PHARMTECH, INC.

$\rightarrow VA$

NaVa



Valproic Acid (VA)


Pyrogallolaldehyde ( PGA) - Benserazide

治療帕金森氏症之中間體 Intermediate for Parkinson's Disease
2個客戶 2 customers

Propiophenone (PPON)
Sales

第一項產品 First product
15個客戶 15 customers

52,253 47,758 37,509 38,665 60,410 - 10,000 20,000 30,000 40,000 50,000 60,000 70,000 2006 2007 2008 2009 2010 2011 2012 Sales Sales
Pent-2
Pentobarbital Sodium
鎮定安眠用之原料藥 API used as calmative
- 2011年開始銷售6佰萬 6mn, starting in 2011. 2012銷售額23佰萬 23mn sales in 2012
第二項產品 Second product 5個客戶 5 customers
4個客戶 4 customers

Hydroxychloroquine
- 2011年開始銷售10.8佰萬 10.8 mn, starting in 2011
- 2012年銷售額33.6佰萬 33.6mn sales in 2012
- 治療風濕性關節炎原料藥(Hydroxychloroquine sulfate) API : Hydroxychloroquine sulfate for rheumarthritis
- 原料藥市場約20噸100 佰萬 API market: 20 MT, 100mn
Anti-inflammatory (Loxoprofen sodium) 2012年銷售5個客戶5佰萬 5 customers, 5 mn sales in 2012. 日本市場200-300公噸,200美金/公斤 Japan market:200-300MT at USD 200/kg

5-HMT – Ritonavir,Lopinavir


5-Wing– Ritonavir,Lopinavir 2012年開始銷售5.7佰萬 5.7mn, starting in 2012 愛滋病藥物之中間體 For AIDS treatment
產品介紹Product
Antidepressant ( Duloxetine ) 2013年底專利到期 Patent will expire in the end of 2013 2011銷售9.5佰萬予10個客戶 9.5 mn sales consisting of 10 customers in 2011 2012年銷售額8佰萬 8 mn sales in 2012 2011及2012年中間體S-MMAA分別銷售2佰萬及1佰萬 S-MMAA(Intermediate) : 2 mn in 2011, 1mn in 2012. 2010年美國市場製劑銷售值美金31億 USD 3.1 billion in formulation in America in 2010

4-CPE Cyclophosphamide:高效能原料藥 Cyclophosphamide: high-potent API


SCÏ
SCI PHARMTECH, INC.


Raw materials 歐、日、中國 大陸進口 From abroad

(原料、溶劑、觸媒)

化工分離(蒸餾、萃取、結晶等) Chemical segregations
GMP Status(GMP現況)
| API | CGMP certified (TFDA) |
CEP (EDQM) |
DMF (USA) |
MF (Japan) |
DMF (Canada) |
|---|---|---|---|---|---|
| Valproic Acid |
2003 | 2004 | 2003 | 2008 | 2008 |
| Allopurinol | 2004 | 2003 | 2011 | ||
| Probucol | 2004 | 2004 | |||
| Sodium Valproate | 2004 | 2006 | |||
| Divalproex Sodium |
2005 | 2005 | 2010 | ||
| Bisoprolol Fumarate | 2006 | ||||
| Pentobarbital Sodium | 2009 | 2011 | |||
| Propafenone Hydrochloride |
2010 | 2012 | 2010 | 2012 | 2012 |
| Methylphenidate HCl | 2011 | ||||
| Duloxetine Hydrochloride | 2012 | 2010/2011 | |||
| Thiopental acid | 2012 | ||||
| Loxoprofen Sodium Hydrate | 2012 | 2011 | |||
| Clindamycin Palmitate HCl | 2011 |

